Research and Markets has announced the addition of the "Polycystic Ovarian Syndrome - Pipeline Review, H2 2016" report to their offering.
'Polycystic Ovarian Syndrome - Pipeline Review, H2 2016'; Polycystic Ovarian Syndrome pipeline therapeutics constitutes close to 10 molecules. Out of which approximately 9 molecules are developed by Companies and remaining by the Universities Institutes.
Furthermore, the publisher says; Polycystic Ovarian Syndrome Polycystic ovary syndrome (PCOS) is a common hormonal disorder among women of reproductive age. Symptoms include menstrual abnormality, acne, thinning hair on the scalp, weight gain, excess androgen and polycystic ovaries. The main risk factor for polycystic ovary syndrome (PCOS) is a family history. Other factors include type 2 diabetes and heart disease. Treatment includes hormone therapy.
The report 'Polycystic Ovarian Syndrome - Pipeline Review, H2 2016' outlays comprehensive information on the therapeutics under development for Polycystic Ovarian Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.
It also reviews of key players involved in therapeutic development for Polycystic Ovarian Syndrome and features dormant and discontinued projects. Currently, The molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 2, 1, 1, 2 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.
Key Topics Covered:
For more information about this report visit http://www.researchandmarkets.com/research/hkpjk2/polycystic
View source version on businesswire.com: http://www.businesswire.com/news/home/20160930005736/en/Business Wire
Last updated on: 30/09/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.